Al Bentley
3 min read
AbbVie has delivered a strong share price run in recent years, and with the stock around US$295 the key question is how firmly its current market value rests on the cash it can generate over time.
-
The stock has returned 203.1% over 5 years, which places substantial expectations into the price and makes the link between that gain and AbbVie’s long term cash generation the central issue.
-
Newer immunology and neuroscience therapies, together with recent licensing deals and acquisitions, can influence how investors assess the durability and timing of the company’s future cash flows.
-
If you’d rather focus on earnings, this one’s for you. See why AbbVie’s 50.6x P/E tells a different valuation story.
The stock’s next move may depend on whether those cash flows, when valued using a Discounted Cash Flow (DCF) approach, are sufficient to support where AbbVie trades today.
If you want more context around AbbVie’s cash flow story, it can help to compare it with other businesses screened using similar valuation and quality criteria such as 32 high quality undervalued stocks.
Is AbbVie Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) model here uses AbbVie’s future free cash flows to estimate what the shares could be worth today. On this approach, the latest twelve month free cash flow sits at about $18.9b, with analyst projections pointing to growing cash generation through the next decade rather than a shrinking base.
Those forecasts build in rising free cash flow into the early 2030s, then taper into more modest growth, which is typical for a large, mature pharmaceutical group. Because the projections already assume continued expansion in therapies like immunology and neuroscience, the model still places AbbVie’s intrinsic value substantially above the current share price of $295.03. The recent update that AbbVie defied its Humira patent cliff with growth from newer drugs helps explain why the DCF can support richer cash flow assumptions than a simple backward looking view might suggest. Find out what AbbVie could be worth using our Discounted Cash Flow (DCF) estimate.
The AbbVie Narrative: What Would Justify Today’s Price?
Simply Wall St Narratives pick up where the AbbVie valuation puzzle leaves off and spell out the specific paths on growth, margins and earnings that would need to hold for the stock to look meaningfully higher or lower than today’s price. Each scenario links a fair value estimate to a particular mix of potential catalysts and risks for AbbVie, so you can track over time which version of the story appears to be taking shape on the Community page.
